Equity · Healthcare
CGEM
NASDAQCullinan Therapeutics (CGEM)
The line runs 19.63 USD on 12 August through 11.72 USD on 9 November, on a scale from 10 to 25. Days the market did not trade hold the previous close, flat.
- Market cap
- 754.2M USD
- 52-week range
- 7 USD – 23 USD
- Avg volume
- 53.6K
as of Nov 9, 2026
Have Cullinan Therapeutics (CGEM) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Cullinan Therapeutics insiders reported 3 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 28 Oct 2025.
Form 4, 90 days to 10 Nov 2026, newest reported trade 5 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 05 Nov 2026 | Michaelson JenniferChief Scientific Officer | Sell | 4,000 | 49K USD |
| 08 Sep 2026 | Michaelson JenniferChief Scientific Officer | Sell | 8,000 | 173K USD |
| 13 Aug 2026 | Michaelson JenniferChief Scientific Officer | Sell | 30,000 | 608K USD |
| Sold | 3 open-market sales | 42,000 | $830K |
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 05 Nov 2026 | Michaelson JenniferChief Scientific Officer | Option exercise | 3,805 | 16K USD |
| 08 Sep 2026 | Michaelson JenniferChief Scientific Officer | Option exercise | 4,000 | 17K USD |
| 13 Aug 2026 | Michaelson JenniferChief Scientific Officer | Option exercise | 30,000 | 129K USD |
Which funds hold Cullinan Therapeutics (CGEM)?
1 of the 45 institutional funds we track reported a Cullinan Therapeutics position for the quarter ended 30 Sep 2026 — a combined 12.3M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Added | 800,961 | 12.3M USD | +2,125.0% |
What has been filed or recorded for Cullinan Therapeutics (CGEM)?
The filings we hold for Cullinan Therapeutics, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 3 reported financial figures, the latest dated 28 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 28 Sep 2026 | Fails to deliver | Shares failed to deliver | 18 shares | 267 USD notional · <0.001% of shares out |
| 30 Jun 2026 | Financials | Total assets | 363.8M USD | at period end |
| 30 Jun 2026 | Financials | Total equity incl. minority interest | 321.8M USD | at period end |
| 31 Dec 2025 | Financials | Net income | −219.9M USD | fiscal year |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.69 USD | |
| 30 Jun 2024 | Quarterly earnings | Q2 2024 reported | EPS −0.75 USD | |
| 31 Mar 2024 | Quarterly earnings | Q1 2024 reported | EPS −0.86 USD | |
| 31 Dec 2023 | Annual report | FY 2023 reported | EPS −3.69 USD | |
| 30 Sep 2023 | Quarterly earnings | Q3 2023 reported | EPS −0.91 USD | |
| 30 Jun 2023 | Quarterly earnings | Q2 2023 reported | EPS −0.82 USD | |
| 31 Mar 2023 | Quarterly earnings | Q1 2023 reported | EPS −1.42 USD | |
| 31 Dec 2022 | Annual report | FY 2022 reported | EPS 2.38 USD |
What do people ask about Cullinan Therapeutics (CGEM)?
What did Cullinan Therapeutics shares close at?11.72
Cullinan Therapeutics closed at 11.72 USD on 9 Nov 2026, up 3.81% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Cullinan Therapeutics’ market cap?754.2M
Cullinan Therapeutics is worth 754.2M USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
Have Cullinan Therapeutics insiders bought or sold shares recently?3 sales
In the 90 days to 10 Nov 2026, Cullinan Therapeutics insiders reported 3 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 28 Oct 2025. A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Cullinan Therapeutics?1 of 45
1 of the 45 funds we track reported a Cullinan Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
When did Cullinan Therapeutics last report earnings?−0.69
Cullinan Therapeutics last reported earnings on 30 Sep 2024 for Q3 2024, with EPS of −0.69 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings